In vivo confocal microscopy assessment of meibomian glands microstructure in patients with Graves’ orbitopathy

Sheng-Nan Cheng
Union Hospital of Tongji Medical College of Huazhong University of Science and Technology

Yue-Qi Yu
Union Hospital of Tongji Medical College of Huazhong University of Science and Technology

Jin Chen
Union Hospital of Tongji Medical College of Huazhong University of Science and Technology

Lin Ye
Union Hospital of Tongji Medical College of Huazhong University of Science and Technology

Xing-Hua Wang (xinghua_wang@hust.edu.cn)
Union Hospital of Tongji Medical College of Huazhong University of Science and Technology

Fa-Gang Jiang
Union Hospital of Tongji Medical College of Huazhong University of Science and Technology

Research article

Keywords: In vivo confocal microscopy, Meibomian glands, Microstructure, Graves’ orbitopathy

DOI: https://doi.org/10.21203/rs.3.rs-45439/v1

License: This work is licensed under a Creative Commons Attribution 4.0 International License.
Read Full License
Abstract

Background: To evaluate microstructural changes in the meibomian glands (MGs) in patients with active and inactive Graves’ orbitopathy (GO), using in vivo confocal microscopy (IVCM), and to investigate the correlations between clinical and confocal findings.

Methods: Forty patients (80 eyes) with GO (34 eyes with active GO, 46 eyes with inactive GO), and 31 age-and sex-matched control participants (62 eyes) were enrolled consecutively. Each participant completed an Ocular Surface Disease Index (OSDI) questionnaire and underwent a full eye examination, including assessments of clinical activity score (CAS), proptosis, palpebral fissure height (PFH), lagophthalmos, lipid layer thickness (LLT), partial blinking rate, noninvasive first breakup time (NIF-BUT), average breakup time (NIAvg-BUT), tear film breakup area (TBUA), corneal fluorescein staining (CFS), Schirmer I Test (SIT), meibum quality and MG expressibility. IVCM of the MGs was performed to determine the MG acinar density (MAD), MG longest and shortest diameters (MALD and MASD), MG orifice area (MOA), MG acinar irregularity (MAI), meibum secretion reflectivity (MSR), acinar wall inhomogeneity (AWI), acinar periglandular interstices inhomogeneity (API), and severity of MG fibrosis (MF).

Results: All parameters demonstrated statistically significant differences among groups (all P < 0.05), except OSDI, LLT and NIAvg-BUT (P > 0.05). Compared to controls, GO groups showed lower MOA and MAD; greater MALD and MASD; and higher degrees of MAI, MSR, AWI, API, and MF (all P < 0.05). Eyes with active GO had higher degrees of MAI, AWI, and API, while eyes with inactive GO had higher degrees of MSR and MF (all P < 0.05). In GO groups, the two measured confocal signs of inflammation (AWI and API) were significantly correlated with CAS, proptosis, PFH, lagophthalmos, OSDI, NIF-BUT, CFS, SIT, meibum quality, and MG expressibility (all P < 0.05). MF was significantly correlated with CAS, OSDI, meibum quality, and MG expressibility (all P < 0.05).

Conclusions: IVCM effectively revealed microstructural changes of MGs in eyes with GO and provided strong in vivo evidence for the roles of obstruction and inflammation in the ocular surface disease process. Furthermore, it revealed discernible patterns of MG abnormalities in eyes with active GO and inactive GO, which are not easily distinguishable by typical clinical examinations.

Background

Graves’ orbitopathy (GO) is an inflammatory autoimmune disorder, that is associated with a combination of environmental, genetic, and immunological factors [1–3]. Ocular surface impairment is common in patients with GO, including conjunctival hyperemia and chemosis, dry eye, superficial punctate keratopathy, exposure keratopathy, and corneal ulcer [4–6]. Dry eye disease (DED) is the most common cause of ocular discomfort found in patients with GO [7]. It has been reported that up to 85% of patients exhibit dry eye [8, 9]. The pathogenesis of DED in patients with GO has not been completely elucidated. Some underlying mechanisms have been proposed. First, mechanical factors (e.g., lid retraction, exophthalmos, lagophthalmos and blinking abnormalities) may cause increased ocular surface area on
both open and closed eyes, thereby enhancing tear evaporation and causing dry eye [10–12]. Second, lacrimal acinar cells physiologically express thyroid-stimulating hormone receptors (TSHR); the antigen antibody reaction involved in GO may lead to lacrimal gland impairment and subsequent reduced volume of reflex tearing [13, 14]. Third, previous studies have confirmed that the composition and quantity of tears in patients with GO differs from that of healthy people, including elevated levels of inflammatory cytokines (e.g., IL-1β, IL-2, IL-17A, IL-6, IL-7, IL-10, and TNF-α) [15–17]. Fourth, the density of conjunctival epithelial cells significantly decreases in patients with GO, while the number of inflammatory cells increases and the number of conjunctival goblet cells decreases [18]. Patients with GO have dull corneal sensation, which leads to incomplete blinking, insufficient lacrimal gland secretion and unstable tear film. Corneal tear secretion is regulated by nerves; in patients with GO, the number of corneal nerve fibers decreases and their curvature increases, resulting in reduced tear secretion [5].

The International Dry Eye Work Shop classifies DED into aqueous tear deficiency and evaporative dry eye [19]. Meibomian gland dysfunction (MGD) is considered a major risk factor for evaporative dry eye [20]. MGD patients suffer from abnormalities of meibomian glands (MGs) in terms of both function and morphology. The anatomical features (i.e., the superficial location of MGs in the tarsal plates) allows MGs to be quantified via noncontact infrared meibography and in vivo confocal microscopy (IVCM). MG dropout refers to the loss of acinar tissue detected by meibography, and several investigators have shown that MG dropout is a useful index of obstructive MGD [21–23]. From a microscopy perspective, IVCM is reportedly useful for describing the morphological alterations of MGs in patients with MGD, such as reduction of MG acinar density, enlargement of acinar diameter, and contraction of MG orifices [24, 25]. IVCM has become an indispensable tool in the study of MGD, allowing direct noninvasive visualization of MG microstructures. Most previous studies focused on aqueous tear deficiency in patients with GO; however, they neglected MGD in these patients. Only a few studies have focused on MGs in patients with GO [26, 27]. Thus, this study used IVCM to examine the morphological changes, particularly in terms of microstructure, in the MGs of patients with GO; it also evaluated correlations of these changes with clinical manifestations of GO.

**Methods**

**Participants**

This cross-sectional, observational study was approved by the Ethics Committee of Union Hospital affiliated to Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China, and was conducted in strict accordance with the Declaration of Helsinki. All participants provided written informed consent prior to enrollment in the study.

Patients diagnosed with GO were enrolled between March 2019 and January 2020 from our clinics. Patients with unilateral or bilateral GO were included. The diagnosis of GO was based on the Bartley criteria [28]. GO activity was classified on the basis of the clinical activity score (CAS) [29]. CAS ≥ 3/7 was considered indicative of active GO; CAS ≤ 2/7 was considered indicative of inactive GO [29]. Patients
were excluded if they met either of the following criteria: presence of any other ophthalmic disorder or additional systemic disease or a history of previous eyelid or orbital surgery. Thirty-one age-and sex-matched patients without GO, who visited our clinics and met the same criteria were enrolled as a control group.

**Clinical Evaluation**

All participants completed a patient history questionnaire including duration of GO; a researcher recorded the CAS for each patient. A complete ophthalmic examination was then performed. The external examination included proptosis, as well as assessments of palpebral fissure height (PFH) and lagophthalmos [30].

For all participants, the ocular surface status was evaluated by assessment of the following parameters: (1) Ocular surface disease index (OSDI), a valid and reliable instrument for measuring the severity of dry eye disease. According to the severity of dry eye symptoms, the OSDI score ranges from 0 to 100; asymptomatic patients are scored as 0 and the most symptomatic patients scored as 100. (2) Tear film lipid layer thickness (LLT) and partial blinking rate (PBR), detected via LipiView® Ocular Surface Interferometer (TearScience, Inc., Morrisville, NC, USA). An interferometric color unit (ICU) represented the lipid distribution; an ICU value of 1 indicated a tear film LLT of 1 nm [31]. Because the exact LLT value cannot be measured or shown precisely by this instrument if the LLT value exceeds 100 nm, the LLT was artificially set to 100 nm for patients in whom LLT was ≥ 100 nm. (3) Noninvasive first breakup time (NIF-BUT), noninvasive average breakup time (NIAvg-BUT), and tear film breakup area (TBUA) [32]. A noninvasive method was used via Sirius (Sirius System CSO, Italian) to measure BUT to assess the stability of the tear film. The total duration of shooting was 17 seconds. (4) Schirmer I Test (SIT), used to evaluate the quantity of tears in each eye. The measurement was performed for 5 minutes without use of topical anesthesia. (5) Corneal fluorescein staining (CFS), in which the cornea was divided into 4 quadrants and each quadrant was graded on a scale of 0 to 3. The total CFS of the 4 quadrants ranged from 0 to 12.

MG dropout was observed by means of noncontact infrared meibography (Sirius System, CSO); the ratio was automatically calculated within the system. Partial or complete loss of MGs was scored using the following grades for lower eyelid: 0, no loss of MGs; 1, area of loss less than one-third of the total MG area; 2, area of loss between one-third and two-thirds; 3, area of loss more than two-thirds [33]. To evaluate meibum quality, MGs in the central parts of the eyelid were assessed using a scale of 0–3: 0, clear fluid; 1, cloudy fluid; 2, cloudy particulate fluid; and 3, inispissated (similar to toothpaste). Five MGs in the central parts of the eyelid were evaluated to evaluate the MG expressibility on a scale of 0–3: 0, all glands expressible; 1, 3–4 glands expressible; 2, 1–2 glands expressible; and 3, no glands expressible [34].

**In Vivo Confocal Microscopy**
IVCM was performed on all subjects with a new-generation confocal microscope (HRT III Corneal Rostock Module, Heidelberg Engineering GmbH, Dossenheim, Germany). The MG acini and orifices were examined; corresponding images were collected and stored. Three non-overlapping, high-quality MG images were randomly selected from the nasal, central, and temporal sides of each lower eyelid (9 total images per eyelid). The following variables were quantitatively determined [32, 35]: (1) MG orifice area (MOA; calculated automatically by ImageJ software, National Institutes of Health, Bethesda, MD, USA), (2) MG acinar density (MAD; acini were manually marked inside each 400*400-µm frame and the density was automatically calculated using the HRT III cell counting system), (3) MG acinar longest diameter (MALD), (4) MG acinar shortest diameter (MASD), (5) MG acinar irregularity (MAI), (6) meibum secretion reflectivity (MSR), (7) acinar wall inhomogeneity (AWI), (8) acinar periglandular interstices inhomogeneity (API), and (9) severity of MG fibrosis (MF). The MAI was assessed on a 4-point scale, with virtually round or elliptical shape as 0, minimal presence of lobulated shaped acinar units as 1, moderate presence as 2 and heavy presence as 3 [36]. The MSR was evaluated on a 4-point scale [36–39]: black secretion color was scored as 0, dark gray color as 1, light gray color as 2, and white color as 3. The AWI and API were each rated on a 4-point scale: absence of punctate reflecting elements was scored as 0, minimal presence of punctate reflecting elements as 1, moderate presence as 2, and heavy presence as 3 [36–39]. The MF was scored on a 3-point scale: no fibrosis was scored as 0, fibrosis in less than half of the lower eyelid as 1, and fibrosis in more than half of the lower eyelid as 2 [40].

**Statistical analysis**

Data analysis was performed using IBM SPSS Statistics for Windows, version 20 (IBM Corp., Armonk, NY, USA). The normality of the data distribution was assessed by means of Shapiro-Wilk test. For each variable, the Kruskal-Wallis test was used to ascertain statistical differences among the three groups. The Mann- Whitney U test, independent t-test, and X² test were used to compare between pairs of groups when necessary. Spearman correlation coefficients were used to determine correlations of confocal microscopy data with clinical data in patients with GO. P < 0.05 was considered statistically significant.

**Results**

**Clinical data**

The demographic and clinical data in GO groups are shown in Table 1. We consecutively enrolled 40 patients with GO (80 eyes; 31 women and 9 men; mean age, 48.26 ± 10.41 years; range, 28–71 years), of which 34 eyes exhibited active GO and 46 eyes exhibited inactive GO. We also enrolled 31 control participants (62 eyes; 21 women and 10 men; mean age, 45.65 ± 14.63 years; range, 18–73 years). Age and gender did not significantly differ among groups (both P <0.05).
Table 1
Clinical data of GO groups and controls.

| Clinical data                        | Active GO (34 eyes) | Inactive GO (46 eyes) | Controls (62 eyes) | p*   |
|--------------------------------------|---------------------|-----------------------|--------------------|------|
| Age, years                           | 50.65 ± 9.49        | 46.50 ± 10.80         | 45.65 ± 14.63      | 0.156\(^a\) |
| Proptosis, mm                        | 19.94 ± 3.83        | 17.63 ± 3.11          | 14.24 ± 1.06       | 0.000\(^b\) |
| Palpebral fissure height, mm         | 11.37 ± 2.03        | 10.18 ± 1.78          | 8.76 ± 0.71        | 0.000\(^c\) |
| Lagophthalmos, mm                    | 0.99 ± 0.95         | 0.26 ± 0.65           | 0.00 ± 0.00        | 0.000\(^d\) |
| CAS                                  | 3.56 ± 0.69         | 0.96 ± 0.72           |                   | 0.000  |
| Duration of GO, months               | 11.24 ± 12.18       | 16.82 ± 21.32         |                   | 0.136  |
| OSDI score                           | 27.49 ± 15.11       | 23.14 ± 10.15         | 22.81 ± 18.93      | 0.345  |
| LLT, nm                              | 73.09 ± 19.46       | 65.76 ± 13.68         | 66.98 ± 19.89      | 0.174  |
| PBR, %                               | 51.74 ± 29.11       | 56.98 ± 25.03         | 37.10 ± 25.30      | 0.000  |
| NIF-BUT, s                           | 6.09 ± 3.72         | 6.78 ± 3.86           | 8.20 ± 4.09        | 0.032  |
| NIAvg-BUT, s                         | 8.26 ± 3.28         | 8.57 ± 3.61           | 9.58 ± 3.46        | 0.153  |
| TBUA, %                              | 8.41 ± 9.65         | 8.16 ± 9.75           | 3.58 ± 5.17        | 0.005  |
| CFS                                  | 2.18 ± 2.15         | 0.72 ± 0.97           | 0.37 ± 0.55        | 0.000  |
| SIT, mm                              | 7.00 ± 5.11         | 9.74 ± 4.00           | 10.77 ± 8.20       | 0.025  |
| MG dropout                           | 1.62 ± 0.77         | 1.00 ± 0.29           | 0.82 ± 0.55        | 0.000  |
| Meibum quality                       | 1.24 ± 0.60         | 1.02 ± 0.61           | 0.66 ± 0.65        | 0.000  |
| MG expressibility                    | 1.09 ± 0.66         | 0.87 ± 0.74           | 0.71 ± 0.68        | 0.044  |

Data are presented as mean ± standard deviation (SD), n (%) or median (range), as appropriate.

* Obtained by Kruskal-Wallis test.

a Active GO vs. Inactive GO: P = 0.078; Active GO vs. Control: P = 0.206; Inactive GO vs. Control: P = 0.960 (Mann-Whitney U test).

b Active GO vs. Inactive GO: P = 0.006; Active GO vs. Control: P = 0.000; Inactive GO vs. Control: P = 0.000 (Mann-Whitney U test).

c Active GO vs. Inactive GO: P = 0.003; Active GO vs. Control: P = 0.000; Inactive GO vs. Control: P = 0.000 (Mann-Whitney U test).
| Clinical data | Active GO (34 eyes) | Inactive GO (46 eyes) | Controls (62 eyes) | p* |
|---------------|---------------------|-----------------------|-------------------|----|
| d Active GO vs. Inactive GO: P = 0.000; Active GO vs. Control: P = 0.000; Inactive GO vs. Control: P = 0.000 (Mann-Whitney U test). |
| e Active GO vs. Inactive GO: P = 0.205; Active GO vs. Control: P = 0.056; Inactive GO vs. Control: P = 0.116 (Mann-Whitney U test). |
| f Active GO vs. Inactive GO: P = 0.069; Active GO vs. Control: P = 0.116; Inactive GO vs. Control: P = 0.891 (Mann-Whitney U test). |
| g Active GO vs. Inactive GO: P = 0.319; Active GO vs. Control: P = 0.019; Inactive GO vs. Control: P = 0.000 (Mann-Whitney U test). |
| h Active GO vs. Inactive GO: P = 0.414; Active GO vs. Control: P = 0.013; Inactive GO vs. Control: P = 0.058 (Mann-Whitney U test). |
| i Active GO vs. Inactive GO: P = 0.922; Active GO vs. Control: P = 0.135; Inactive GO vs. Control: P = 0.143 (Mann-Whitney U test). |
| j Active GO vs. Inactive GO: P = 0.545; Active GO vs. Control: P = 0.000; Inactive GO vs. Control: P = 0.006 (Mann-Whitney U test). |
| k Active GO vs. Inactive GO: P = 0.000; Active GO vs. Control: P = 0.000; Inactive GO vs. Control: P = 0.092 (Mann-Whitney U test). |
| l Active GO vs. Inactive GO: P = 0.002; Active GO vs. Control: P = 0.037; Inactive GO vs. Control: P = 0.501 (Mann-Whitney U test). |
| m Active GO vs. Inactive GO: P = 0.000; Active GO vs. Control: P = 0.000; Inactive GO vs. Control: P = 0.041 (Mann-Whitney U test). |
| n Active GO vs. Inactive GO: P = 0.126; Active GO vs. Control: P = 0.000; Inactive GO vs. Control: P = 0.004 (Mann-Whitney U test). |
| o Active GO vs. Inactive GO: P = 0.101; Active GO vs. Control: P = 0.011; Inactive GO vs. Control: P = 0.298 (Mann-Whitney U test). |
| GO, Graves’ orbitopathy; CAS, clinical activity score; OSDI, ocular surface disease index; LLT, tear film lipid layer thickness; PBR, partial blinking rate; NIF-BUT, noninvasive first breakup time; NIAvg-BUT, noninvasive average breakup time; TBUA, tear film breakup area; CFS, corneal fluorescein staining; SIT, Schirmer I test. |

All clinical parameters showed statistically significant differences among groups (all P < 0.05), except duration of GO, OSDI, LLT and NIAvg-BUT (all P > 0.05). PBR, NIF-BUT, TBUA and meibum quality in GO groups were significantly different from those parameters in controls (all P < 0.05), but were not different between GO groups (all P > 0.05). CFS and SIT in the active GO group were significantly different from those parameters in the inactive GO group and controls (all P < 0.05), but were not different between the inactive GO group and controls (all P > 0.05). MG expressibility was significantly different merely between the active GO group and controls (P < 0.05). MG dropout was significantly greater in GO groups than in controls (all P < 0.05), with values higher in the active GO group than in the inactive GO group (P = 0.0001) (Fig. 1).
Mg Confocal Data

All confocal microscopy assessments of MGs significantly differed among groups (all P<0.0001) (Table 2). MOA and MAD were significantly lower in active and inactive GO groups than in controls (all P<0.0001), and MALD and MASD were significantly greater in active and inactive GO groups than in controls (all P<0.0001); however, these four parameters did not differ between GO groups (all P>0.05) (Figs. 2 and 3). AWI and API were significantly higher in the active GO group than in the inactive GO group and controls (all P<0.0001), but did not differ between the inactive GO group and controls (both P>0.05) (Fig. 4). MAI and MSR appeared significantly higher in the active and inactive GO groups, compared to controls (all P<0.05); MAI was more pronounced in the active GO group, while MSR was more pronounced in the inactive GO group (both P<0.05) (Fig. 4). MF was significantly greater in GO groups than in controls (both P<0.05), with values higher in the inactive GO group than in the active GO group (P<0.05) (Fig. 5).
Table 2
The confocal microscopy parameters of meibomian glands.

| Parameters | Active GO (34 eyes) | Inactive GO (46 eyes) | Control (62 eyes) | P* |
|------------|---------------------|-----------------------|-------------------|----|
| MOA, µm²  | 1985.82 ± 1325.30   | 2021.59 ± 1367.45     | 3896.63 ± 891.90  | 0.000<sup>a</sup> |
| MAD, /mm² | 87.21 ± 32.69       | 80.72 ± 35.54         | 114.69 ± 34.90    | 0.000<sup>b</sup> |
| MALD, µm  | 118.11 ± 30.23      | 120.58 ± 27.64        | 58.68 ± 20.28     | 0.000<sup>c</sup> |
| MASD, µm  | 44.77 ± 19.16       | 46.02 ± 20.70         | 27.80 ± 9.90      | 0.000<sup>d</sup> |
| MAI       | 1.59 ± 0.60         | 1.26 ± 0.49           | 0.71 ± 0.61       | 0.000<sup>e</sup> |
| MSR       | 1.21 ± 0.40         | 1.76 ± 0.73           | 0.94 ± 0.67       | 0.000<sup>f</sup> |
| AWI       | 1.94 ± 0.76         | 0.89 ± 0.60           | 0.97 ± 0.74       | 0.000<sup>g</sup> |
| API       | 2.06 ± 0.68         | 1.04 ± 0.62           | 0.90 ± 0.64       | 0.000<sup>h</sup> |
| MF        | 0.65 ± 0.59         | 0.93 ± 0.48           | 0.37 ± 0.55       | 0.000<sup>i</sup> |

Data are presented as mean ± standard deviation (SD), n (%) or median (range), as appropriate.

* Obtained by Kruskal-Wallis test.

<sup>a</sup> Active GO vs. Inactive GO: P = 0.793; Active GO vs. Control: P = 0.000 (Mann-Whitney U test).

<sup>b</sup> Active GO vs. Inactive GO: P = 0.302; Active GO vs. Control: P = 0.001 (Mann-Whitney U test).

<sup>c</sup> Active GO vs. Inactive GO: P = 0.543; Active GO vs. Control: P = 0.000 (Mann-Whitney U test).

<sup>d</sup> Active GO vs. Inactive GO: P = 0.701; Active GO vs. Control: P = 0.000 (Mann-Whitney U test).

<sup>e</sup> Active GO vs. Inactive GO: P = 0.015; Active GO vs. Control: P = 0.000 (Mann-Whitney U test).

<sup>f</sup> Active GO vs. Inactive GO: P = 0.000; Active GO vs. Control: P = 0.040 (Mann-Whitney U test).

<sup>g</sup> Active GO vs. Inactive GO: P = 0.000; Active GO vs. Control: P = 0.720 (Mann-Whitney U test).

<sup>h</sup> Active GO vs. Inactive GO: P = 0.000; Active GO vs. Control: P = 0.209 (Mann-Whitney U test).

<sup>i</sup> Active GO vs. Inactive GO: P = 0.017; Active GO vs. Control: P = 0.020; Inactive GO vs. Control: P = 0.000 (Mann-Whitney U test).
| Parameters | Active GO (34 eyes) | Inactive GO (46 eyes) | Control (62 eyes) | p* |
|-----------|-------------------|----------------------|------------------|----|
| MG, meibomian gland; MOA, MG orifice area; MAD, MG acinar density; MALD, MG acinar longest diameter; MASC, MG acinar shortest diameter; MAI, MG acinar irregularity; MSR, meibum secretion reflectivity; AWI, acinar wall inhomogeneity; API, acinar periglandular interstitices inhomogeneity; MF, severity of MG fibrosis. |

**Correlations Between Clinical Data And MG Confocal Data**

Correlations between clinical data of patients with GO and MG confocal microscopy parameters were analyzed using Spearman correlation coefficients. The CAS score was negatively correlated with MSR and MF, and was positively correlated with the degrees of MAI, AWI and API (all $P < 0.05$). Proptosis, PFH, and lagophthalmos were positively correlated with API (all $P < 0.05$); lagophthalmos was also positively correlated with AWI ($P < 0.01$). The OSDI score was positively correlated with the degrees of MAI, AWI, and MF (all $P < 0.05$). The NIF-BUT was positively correlated with MSR ($P < 0.05$), but was negatively correlated with AWI ($P < 0.05$). The CFS score was positively correlated with the degrees of MAI, AWI, and API (all $P < 0.01$). The SIT was positively correlated with MSR ($P < 0.01$), but was negatively correlated with API ($P < 0.05$). MG dropout was positively correlated with the degrees of MAI, AWI, and API (all $P < 0.0001$). Meibum quality and MG expressibility were positively correlated with the degrees of MAI, AWI, API, and MF (all $P < 0.05$).

**Discussion**

IVCM has been recently applied to the armament of modalities used in the examination of MGs in patients with MGD, as well as many other ocular diseases (e.g., Sjogren's syndrome [37], atopic keratoconjunctivitis [41] and primary blepharospasm [36]), providing a new noninvasive tool with which to study morphological changes in MGs. IVCM has been used by several researchers to investigate the effects of GO on the human cornea and bulbar conjunctiva at a cellular level [6, 18, 42]. Their observations suggested that GO induced changes in the bulbar conjunctiva, including reduced epithelial cell density and goblet cell density, increased Langerhans cell density, and higher degree of squamous metaplasia. GO also induced changes in the cornea, such as reduced corneal sensitivity, elevated numbers of corneal Langerhans cells, and abnormal corneal subbasal nerves. We determined microstructural changes of MGs in patients with GO, including lower MOA and MAD; greater MALD and MASC; and higher degrees of MAI, MSR, AWI, API, and MF, compared with age- and gender-matched controls. Moreover, the active GO group had higher degrees of MAI, AWI, and API, as well as lower degrees of MSR and MF, compared with the inactive GO group. Most of our evidence suggests that an obstructive and inflammatory pathogenic mechanism contributes to morphological changes of MGs in patients with GO. To the best of our knowledge, our study is the first to use IVCM for analysis of differences in MG microstructure of patients with active and inactive GO.
Several causative mechanisms have been proposed to initiate the onset of dry eye in patients with GO, including MG abnormalities. Kim et al. [43] suggested that absence of blinking in GO patients led to reduced secretion from MGs. This hypothesis was supported by the findings in a recent study by Park et al. [44], who observed that incomplete blinking and loss of MGs structure in the upper eyelid were more prominent in patients with GO than in dry eye patients. Moreover, CAS affected the structural loss of MGs in patients with GO. These results suggested that incomplete blinking and inflammation might be a major causative mechanism for MG changes in GO patients. In the present study, the structural loss of MGs (macrostructural MG dropout and microstructural MAD) was greater in GO groups than in controls; the active GO group had significantly greater loss of MGs than the inactive GO group. We postulated that this phenomenon can be attributed to the enhancement of incomplete blinking due to proptosis and palpebral fissure widening in patients with GO, with reduction of MG secretion and resultant obstruction. Our study showed that the PBR was significantly higher in GO groups, compared to controls; proptosis, PFH, and lagophthalmos were highest in the active GO group, which supports our hypothesis. Achtsidis et al. [45] reported that dry eye was common in early GO even in the absence of apparent proptosis; it was associated with CAS and reduced corneal sensitivity, which was consistent with our assumption that reduced corneal sensitivity in patients with GO could also lead to enhanced incomplete blinking, and MG dysfunction.

Several studies have shown strong associations between MG dysfunction and inflammatory ocular surface diseases [21, 46–48]. Villani et al. [5] found significant differences in the number of hyperreflective keratinocytes between eyes with active and inactive GO by using corneal confocal microscopy. Previous researchers reported that tear concentrations of cytokines IL-1β, IL-2, IL-17A, IL-6, IL-7, IL-10, and TNF-α were significantly higher in patients with GO; moreover, there were significantly positive correlations between some of the indicator levels and CAS [15–17]. Yoon et al. [49] demonstrated tear nerve growth factor concentrations might have a specific role in ocular surface inflammation, which protected against ocular surface damage in patients with active GO. Anti-inflammatory treatment significantly reduced the nerve growth factor level in tears, increased tear film stability and production, and diminished congestive symptoms. Wang et al. [27] also described functional and morphological MG alterations in patients with GO. Notably, they found that patients with active GO had more severe MG dropout. They assumed that active GO may cause periglandular MG inflammation, leading to MG dropout. These results indicated that orbital inflammation may be involved in ocular surface damage in patients with GO. Thus, GO-associated ocular surface inflammation might cause periglandular inflammation and subsequent MG dysfunction.

Previous studies reported that patients with obstructive MGD showed comparative morphological changes including MG loss, greater acinar diameters, higher secretion reflectivity, and greater AWI and API [24, 37, 41]. These alterations may be due to qualitative changes in MG secretion (inspissation, increased viscosity, and build-up) and resultant MG obstruction. Thus, the MGs of patients with MGD and those with GO differ only in terms of MG orifice size. We hypothesized that the reduced orifice area in patients with GO might involve inflammatory-mediated fibrosis and duct atrophy, with difficulty meibum secretion and resultant orifice obstruction. The gland productivity continues, but meibum cannot be secreted and
the lipid pool storage increases. This leads to acinar unit dilation and enhanced values of MALD and MASD.

The MAI and MSR significantly increased in both active and inactive GO groups; however, the degree of MAI was more pronounced in active the GO group, while the degree of MSR was more pronounced in the inactive GO group. These alterations might be translated to glandular structural disorder and enhanced lipid pool storage, respectively. In our study, the duration of GO was longer in the inactive GO group (16.82 ± 21.32 months) than in the active GO group (11.24 ± 12.18 months). The natural history of GO is characterized by an active inflammatory phase of approximately 1–3 years, followed by an inactive fibrotic phase; thus, combined with the finding that the degree of MF was greater in the inactive GO group, we inferred that MG fibrosis resulted in lipid deposition in acini, which ultimately led to the most pronounced MSR in eyes with inactive GO. Concurrently, inflammation-mediated irregularities in acinar structures were more prominent in eyes with active GO. This aspect was supported by the positive correlation between MAI and CAS, and the negative correlation between MSR and CAS.

In our study, the AWI and API also significantly increased in the active GO group, compared to the inactive GO group and controls. As suggested by Villani et al. [37, 38] for other conditions, the enhanced inhomogeneity may constitute a sign of inflammation in the tarsus and MGs. However, Osama et al. [41] found confocal microscopy evidence of MG fibrosis in patients with atopic keratoconjunctivitis, which may lead to the enhanced API. Our study did not reveal direct evidence of inflammation (e.g., dendritic cells) in eyes with GO. Previous studies demonstrated that quantitative dendritic cell density could reveal periglandular inflammation [24, 50]. In our study, the typical dendritic shape was often unrecognizable and individual cells could not be clearly identified by using IVCM. Thus, we chose to perform a semiquantitative evaluation of punctiform elements visible in the interstices. Furthermore, we found strong positive correlations of both AWI and API with CAS. Therefore, we regarded the AWI and API as confocal microscopy signs of eyelid margin and tarsal inflammation. In this study, we also investigated the confocal microscopy signs of the degree of MG fibrosis, which was significantly greater in the active and inactive GO groups, compared to controls. We suspect that MG fibrosis is exacerbated by inflammation involving interactions between inflammatory cells and fibroblasts; subsequent activation leads to pathogenic fibrosis in the MG microenvironment.

We found that eyes with GO were characterized by greater MG dropout, tear film instability (shorter BUT), and ocular surface epithelial damage (higher CFS), as well as worser MG secretion; some of these findings were consistent with previous reports [27, 43, 44]. In our study, the SIT between the inactive GO group and controls showed no significant difference. However, in patients with active GO, tear secretion was significantly reduced, compared to the inactive GO group and controls. These results were consistent with some previous studies [13, 44], although others demonstrated conflicting findings [27, 51]. Eckstein et al. [13] reported that high TSHR autoantibody activity in patients with active GO might impair the lacrimal gland, which could physiologically express TSHR. Notably, we found no significant differences in LLT among the active GO group, inactive GO group, and controls; this finding was parallel with the results of Wang et al. [4] As suggested by Park et al., we also
consider that the number of blinks must be compared to investigate LLT in the active and inactive GO groups. Otherwise, it was not convincing to explain why a thicker LLT but higher MGD in eyes with active GO, solely on the basis of lagophthalmos-mediated forceful blinking.

There were some limitations in this study. First, we only performed confocal microscopy analysis of the inferior eyelid margin. Confocal examination requires a few minutes of contact between the instrument and examined tissue, which can be uncomfortable for the subject. Moreover, the examination involves a fixed orientation, in which the examined tissue must be positioned parallel to the face of the sterile cap. The inferior eyelid margin provides a less invasive approach for the visualization of glandular structures. Second, the control group is not representative of the healthy population. Some participants in the control group also had dry eye symptoms and inadequate MG performance, but these characteristics did not appear to bias our findings. Third, we designated LLT as 100 nm for eyes with LLT > 100 nm, which may have caused underestimation of the average LLT value. The exact LLT value cannot be measured precisely or shown by this instrument if it exceeds 100 nm, which is the limit of the measuring instrument; we cannot improve this measurement without a more accurate measuring instrument.

**Conclusions**

IVCM offers a new approach for in vivo noninvasive histopathological evaluations of MGs in eyes with GO. Our study revealed new evidence regarding the pathologic morphological changes of MGs in eyes with GO and provided strong in vivo evidence for the roles of obstruction and inflammation in the ocular surface disease process. These findings aid in elucidating mechanism underlying GO-associated dry eye. Moreover, these findings showed that active and inactive GO can be identified by their discernible patterns of MG abnormalities, whereas they cannot be easily distinguished by typical clinical examinations. In patients with active GO, we commonly observed confocal microscopy signs of inflammation and slight dilative morphological changes; in patients with inactive GO, we commonly observed signs of glandular obstruction, distension, and fibrosis.

**Abbreviations**

GO: Graves’ orbitopathy; CAS: clinical activity score; OSDI: ocular surface disease index; LLT: tear film lipid layer thickness; PBR: partial blinking rate; NIF-BUT: noninvasive first breakup time; NIAvg-BUT: noninvasive average breakup time; TBUA: tear film breakup area; CFS: corneal fluorescein staining; SIT: Schirmer I test; MG: meibomian gland; MOA: MG orifice area; MAD: MG acinar density; MALD: MG acinar longest diameter; M ASD: MG acinar shortest diameter; MAI: MG acinar irregularity; MSR: meibum secretion reflectivity; AWI: acinar wall inhomogeneity; API: acinar periglandular interstices inhomogeneity; MF: severity of MG fibrosis.

**Declarations**

**Acknowledgements**
The authors would like to acknowledge all members of the Department of Ophthalmology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology.

**Funding**

This work was supported by the National Natural Science Foundation of China (No.81900912). The funding organization had no role in the design or conduct of this study.

**Availability of data and material**

The datasets used and analyzed during the current study are available from the corresponding authors on reasonable request.

**Authors’ contributions**

Conception and design (SNC, XHW, FGJ); data collection (SNC, YQY, JC); analysis and interpretation of data (SNC, LY, XHW); statistical analysis (SNC); literature search (SNC); writing the article (SNC); critical revision of the article (SNC, YQY, JC, LY, XHW, FGJ). All authors reviewed and approved the final manuscript.

**Competing interests**

The authors declare that they have no competing interests.

**Consent for publication**

Not Applicable.

**Ethics approval and consent to participate**

This study was approved by the Ethics Committee of Union Hospital affiliated to Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China, and was conducted in strict accordance with the Helsinki Declaration. All participants provided written informed consent.

**References**

1. Sabini E, Leo M, Mazzi B, et al. Does Graves’ Orbitopathy Ever Disappear? Answers to an Old Question. Eur Thyroid J. 2017;6(5):263-270.

2. Rotondo Dottore G, Torregrossa L, Caturegli P, et al. Association of T and B Cells Infiltrating Orbital Tissues With Clinical Features of Graves Orbitopathy. JAMA Ophthalmol. 2018;136(6):613-619.

3. Fang S, Huang Y, Liu X, et al. Interaction Between CCR6+ Th17 Cells and CD34+ Fibrocytes Promotes Inflammation: Implications in Graves’ Orbitopathy in Chinese Population. Invest Ophthalmol Vis Sci. 2018;59(6):2604-2614.
4. Novaes P, Grisolia ABD, Smith TJ. Update on thyroid-associated Ophthalmopathy with a special emphasis on the ocular surface. Clin Diabetes Endocrinol. 2016;2(1):19.

5. Edoardo V, Francesco V, Roberto S, et al. Corneal Involvement in Graves' Orbitopathy: An In Vivo Confocal Study. Invest Ophthalmol Vis Sci. 2010;51(9):4574-4578.

6. Wu LQ, Cheng JW, Cai JP, et al. Observation of Corneal Langerhans Cells by In Vivo Confocal Microscopy in Thyroid-Associated Ophthalmopathy. Curr Eye Res. 2016;41(7):927-932.

7. Bartley GB, Fatourechi V, Kadmas EF, Jacobsen SJ, Gorman CA. Clinical Features of Graves’ Ophthalmopathy in an Incidence Cohort. Am J Ophthalmol. 1996;121(3):284-290.

8. Gürdal C, Sarac Ö, Genç İ, Kırımlıoğlu H, Takmaz T, Can İ. Ocular Surface and Dry Eye in Graves' Disease. Curr Eye Res. 2011;36(1):8-13.

9. Bartley GB, Fatourechi V, Kadmas EF, et al. Long-term Follow-up of Graves Ophthalmopathy in an Incidence Cohort. Ophthalmology. 1996;103(6):958-962.

10. Sokol JA, Foulks GN, Haider A, Nunery WR. Ocular Surface Effects of Thyroid Disease. Ocul Surf. 2010;8(1):29-39.

11. Gilbard JP, Farris RL. Ocular surface drying and tear film osmolarity in thyroid eye disease. Acta Ophthalmol. 1983;61(1):108-116.

12. Cruz AAV, Ribeiro SFT, Garcia DM, Akaishi PM, Pinto CT. Graves Upper Eyelid Retraction. Surv Ophthalmol. 2013;58(1):63-76.

13. Eckstein AK, Finkenrath A, Heiligenhaus A, et al. Dry eye syndrome in thyroid associated ophthalmopathy: lacrimal expression of TSH receptor suggests involvement of TSHR-specific autoantibodies. Acta Ophthalmol Scand. 2004;82(3 Pt 1):291-297.

14. Chang TC, Huang KM, Chang TJ, Lin SL. Correlation of orbital computed tomography and antibodies in patients with hyperthyroid Graves' disease. Clin Endocrinol. 1990;32(5):551-558.

15. Huang D, Luo Q, Yang H, Mao Y. Changes of lacrimal gland and tear inflammatory cytokines in thyroid-associated ophthalmopathy. Invest Ophthalmol Vis Sci. 2014;55(8):4935-4943.

16. Cai K, Wei R. Interleukin-7 expression in tears and orbital tissues of patients with Graves’ ophthalmopathy. Endocrine. 2013;44(1):140-144.

17. Huang D, Xu N, Song Y, Wang P, Yang H. Inflammatory cytokine profiles in the tears of thyroid-associated ophthalmopathy. Graefes Arch Clin Exp Ophthalmol. 2012;250(4):619-625.

18. Wei YH, Chen WL, Hu FR, Liao SL. In vivo confocal microscopy of bulbar conjunctiva in patients with Graves' ophthalmopathy. J Formos Med Assoc. 2015;114(10):965-972.

19. Lemp MA. Report of the National eye Institute/industry workshop on clinical trials in dry eyes. CLAO J. 1995;21(4):221-232.

20. Viso E, Gude F, Rodriguez-Ares MT. The association of meibomian gland dysfunction and other common ocular diseases with dry eye: a populationbased study in Spain. Cornea. 2011;30(1):1-6.

21. Shimazaki J, Goto E, Ono M, Shimmura S, Tsubota K. Meibomian gland dysfunction in patients with Sjogren syndrome. Ophthalmology. 1998;105(8):1485-1488.
22. Robin JB, Jester JV, Nobe J, Nicolaides N, Smith RE. In Vivo Transillumination Biomicroscopy and Photography of Meibomian Gland Dysfunction. Ophthalmology. 1985;92(10):1423-1426.

23. Mathers WD, Shields WJ, Sachdev MS, Matthew Petroll W, Jester JV. Meibomian gland morphology and tear osmolarity: changes with Accutane therapy. Cornea. 1991;10(4):286-290.

24. Matsumoto Y, Sato EA, Ibrahim OM, Dogru M, Tsubota K. The application of in vivo laser confocal microscopy to the diagnosis and evaluation of meibomian gland dysfunction. Mol Vis. 2008;14(149-151):1263-1271.

25. Matsumoto Y, Shigeno Y, Sato EA, et al. The evaluation of the treatment response in obstructive meibomian gland disease by in vivo laser confocal microscopy. Graefes Arch Clin Exp Ophthalmol. 2009;247(6):821-829.

26. Vagge A, Bernabei F, Del Noce C, et al. In Vivo Confocal Microscopy Morphometric Analysis of Meibomian Glands in Patients With Graves Ophthalmopathy [published online ahead of print, 2020 Jun 30]. Cornea. 2020;10.1097/ICO.0000000000002404. doi:10.1097/ICO.0000000000002404

27. Wang CY, Ho RW, Fang PC, et al. The function and morphology of Meibomian glands in patients with thyroid eye disease: a preliminary study. BMC Ophthalmol. 2018;18(1):90.

28. Bartley GB, Gorman CA. Diagnostic Criteria for Graves' Ophthalmopathy. Am J Ophthalmol. 1995;119(6):792-795.

29. Bartalena L, Baldeschi L, Boboridis K, et al. The 2016 European Thyroid Association/European Group on Graves' Orbitopathy Guidelines for the Management of Graves' Orbitopathy. Eur Thyroid J. 2016;5(1):9-26.

30. Pereira MV, Gloria AL. Lagophthalmos. Semin Ophthalmol. 2010;25(3):72-78.

31. Zhao Y, Tan CL, Tong L. Intra-observer and inter-observer repeatability of ocular surface interferometer in measuring lipid layer thickness. BMC Ophthalmol. 2015;15:53.

32. Cheng SN, Jiang FG, Chen H, Gao H, Huang YK. Intense Pulsed Light Therapy for Patients with Meibomian Gland Dysfunction and Ocular Demodex Infestation. Curr Med Sci. 2019;39(5):800-809.

33. Tomlinson A, Bron AJ, Korb DR, et al. The international workshop on meibomian gland dysfunction: report of the diagnosis subcommittee. Invest Ophthalmol Vis Sci. 2011;52(4):2006-2049.

34. Arita R, Itoh K, Inoue K, Amano S. Noncontact infrared meibography to document age-related changes of the meibomian glands in a normal population. Ophthalmology. 2008;115(5):911-915.

35. Cheng SN, Zhang MC, Chen H, Fan WL, Huang YK. The correlation between the microstructure of meibomian glands and ocular Demodex infestation: A retrospective case-control study in a Chinese population. Medicine (Baltimore). 2019;98(19):e15595.

36. Lin T, Gong L. In vivo confocal microscopy of meibomian glands in primary blepharospasm: A prospective case-control study in a Chinese population. Medicine (Baltimore). 2016;95(23):e3833.

37. Villani E, Beretta S, De Capitani M, Galimberti D, Viola F, Ratiglia R. In vivo confocal microscopy of meibomian glands in Sjogren's syndrome. Invest Ophthalmol Vis Sci. 2011;52(2):933-939.
38. Villani E, Ceresara G, Beretta S, Magnani F, Viola F, Ratiglia R. In vivo confocal microscopy of meibomian glands in contact lens wearers. Invest Ophthalmol Vis Sci. 2011;52(8):5215-5219.

39. Agnili L, Fasanella V, Costagliola C, et al. In vivo confocal microscopy of meibomian glands in glaucoma. Br J Ophthalmol. 2013;97(3):343-349.

40. Ban Y, Ogawa Y, Ibrahim OMA, et al. Morphologic evaluation of meibomian glands in chronic graft-versus-host disease using in vivo laser confocal microscopy. Mol Vis. 2011;17:2533-2543.

41. Ibrahim OM, Matsumoto Y, Dogru M, et al. In vivo confocal microscopy evaluation of meibomian gland dysfunction in atopic-keratoconjunctivitis patients. Ophthalmology. 2012;119(10):1961-1968.

42. Wu LQ, Mou P, Chen ZY, et al. Altered Corneal Nerves in Chinese Thyroid-Associated Ophthalmopathy Patients Observed by In Vivo Confocal Microscopy. Med Sci Monit. 2019;25:1024-1031.

43. Kim YS, Kwak AY, Lee SY, Yoon JS, Jang SY. Meibomian gland dysfunction in Graves' orbitopathy. Can J Ophthalmol. 2015;50(4):278-282.

44. Park J, Baek S. Dry eye syndrome in thyroid eye disease patients: The role of increased incomplete blinking and Meibomian gland loss. Acta Ophthalmologica. 2018;97(5):e800-e806.

45. Achtsidis V, Tentolouris N, Theodoropoulou S, et al. Dry eye in Graves ophthalmopathy: correlation with corneal hypoaesthesia. Eur J Ophthalmol. 2013;23(4):473-479.

46. Mathers WD, Shields WJ, Sachdev MS, Matthew Petroll W, Jester JV. Meibomian gland dysfunction in chronic blepharitis. Cornea. 1991;10(4):277-285.

47. Mathers WD, Billborough M. Meibomian Gland Function and Giant Papillary Conjunctivitis. Am J Ophthalmol. 1992;114(2):188-192.

48. Knop E, Knop N. Meibomian glands: part IV. Functional interactions in the pathogenesis of meibomian gland dysfunction (MGD). Ophthalmologe. 2009;106(11):980-987.

49. Yoon JS, Choi SH, Lee JH, Lee SJ, Lee SY. Ocular surface inflammation, and nerve growth factor level in tears in active thyroid-associated ophthalmopathy. Graefes Arch Clin Exp Ophthalmol. 2010;248(2):271-276.

50. Ibrahim OM, Matsumoto Y, Dogru M, et al. The efficacy, sensitivity, and specificity of in vivo laser confocal microscopy in the diagnosis of meibomian gland dysfunction. Ophthalmology. 2010;117(4):665-672.

51. Gupta A, Sadeghi PB, Akpek EK. Occult thyroid eye disease in patients presenting with dry eye symptoms. Am J Ophthalmol. 2009;147(5):919-923.

Figures
Figure 1

Meibomian gland (MG) dropout. MG dropout was higher in the active and inactive Graves’ orbitopathy (GO) groups, compared to controls, in which the active GO group was most pronounced. (A) Controls. (B) Active GO group. (C) Inactive GO group.

Figure 2

Meibomian gland (MG) acinar density (MAD), MG acinar longest diameter (MALD) and MG acinar shortest diameter (MASD). MAD was decreased, and MALD and MASD were increased in the active and inactive Graves’ orbitopathy (GO) groups, compared to controls; however, those parameters were comparative between the active GO and inactive GO groups. (A) Controls. (B) Active GO group. (C) Inactive GO group.
Figure 3

Meibomian gland orifice. Meibomian gland orifice area (MOA) was decreased in the active and inactive Graves’ orbitopathy (GO) groups, compared to controls; however, MOA was comparative between the active GO and inactive GO groups. (A) Controls. (B) Active GO group. (C) Inactive GO group.

Figure 4

Meibomian gland acinar irregularity (MAI), meibum secretion reflectivity (MSR), acinar wall inhomogeneity (AWI), acinar periglandular interstices inhomogeneity (API). The degrees of MAI, MSR, AWI and API were higher in the active and inactive Graves’ orbitopathy (GO) groups, compared to controls; however, the degrees of MAI, AWI and API were most pronounced in the active GO group, while MSR most pronounced in the inactive GO group. (A) Controls. (B) Active GO group. (C) Inactive GO group.
Figure 5

Meibomian gland fibrosis (MF). The severity of MF was increased in the active and inactive Graves’ orbitopathy (GO) groups, compared to controls, among which the inactive GO group was most pronounced. (A) Controls. (B) Active GO group. (C) Inactive GO group.